JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Syndax Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

13.59 -7.55

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

13

Макс.

14.01

Ключевые показатели

By Trading Economics

Доход

13M

-72M

Продажи

18M

38M

Рентабельность продаж

-189.28

Сотрудники

270

EBITDA

20M

-64M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+151.29% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

4 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

448M

1.3B

Предыдущая цена открытия

21.14

Предыдущая цена закрытия

13.59

Новостные настроения

By Acuity

34%

66%

80 / 371 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Syndax Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 окт. 2025 г., 18:41 UTC

Отчет

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 окт. 2025 г., 18:31 UTC

Отчет

Correction to Procter & Gamble to Focus on Innovation

24 окт. 2025 г., 16:25 UTC

Главные движущие силы рынка

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 окт. 2025 г., 21:07 UTC

Отчет

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 окт. 2025 г., 20:58 UTC

Отчет

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 20:40 UTC

Отчет

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 окт. 2025 г., 20:24 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:23 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:13 UTC

Отчет

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 20:07 UTC

Обсуждения рынка

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 окт. 2025 г., 19:40 UTC

Обсуждения рынка

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 окт. 2025 г., 19:35 UTC

Обсуждения рынка

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 окт. 2025 г., 19:33 UTC

Отчет

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 окт. 2025 г., 19:29 UTC

Обсуждения рынка

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 окт. 2025 г., 18:52 UTC

Отчет

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 окт. 2025 г., 18:41 UTC

Отчет

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 окт. 2025 г., 18:03 UTC

Отчет

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 окт. 2025 г., 18:02 UTC

Отчет

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 окт. 2025 г., 18:00 UTC

Обсуждения рынка

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 окт. 2025 г., 16:57 UTC

Отчет

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 окт. 2025 г., 16:54 UTC

Обсуждения рынка

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 окт. 2025 г., 16:44 UTC

Обсуждения рынка
Отчет

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 окт. 2025 г., 16:39 UTC

Обсуждения рынка
Отчет

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 окт. 2025 г., 16:33 UTC

Отчет

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 16:23 UTC

Отчет

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 16:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 16:07 UTC

Отчет

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Сравнение c конкурентами

Изменение цены

Syndax Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

151.29% рост

Прогноз на 12 месяцев

Средняя 34 USD  151.29%

Максимум 56 USD

Минимум 17 USD

Основано на мнении 12 аналитиков Wall Street, спрогнозировавших целевые цены для Syndax Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

12 ratings

11

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

9.91 / 14.15Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

80 / 371Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
help-icon Live chat